220 related articles for article (PubMed ID: 23898048)
1. In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption.
Wang SP; Daniels E; Chen Y; Castro-Perez J; Zhou H; Akinsanya KO; Previs SF; Roddy TP; Johns DG
J Lipid Res; 2013 Oct; 54(10):2858-65. PubMed ID: 23898048
[TBL] [Abstract][Full Text] [Related]
2. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
[TBL] [Abstract][Full Text] [Related]
3. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
Niesor EJ; Magg C; Ogawa N; Okamoto H; von der Mark E; Matile H; Schmid G; Clerc RG; Chaput E; Blum-Kaelin D; Huber W; Thoma R; Pflieger P; Kakutani M; Takahashi D; Dernick G; Maugeais C
J Lipid Res; 2010 Dec; 51(12):3443-54. PubMed ID: 20861162
[TBL] [Abstract][Full Text] [Related]
4. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters.
Castro-Perez J; Briand F; Gagen K; Wang SP; Chen Y; McLaren DG; Shah V; Vreeken RJ; Hankemeier T; Sulpice T; Roddy TP; Hubbard BK; Johns DG
J Lipid Res; 2011 Nov; 52(11):1965-73. PubMed ID: 21841206
[TBL] [Abstract][Full Text] [Related]
5. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.
van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK
J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430
[TBL] [Abstract][Full Text] [Related]
6. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
7. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
[TBL] [Abstract][Full Text] [Related]
8. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Niesor EJ
Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
[TBL] [Abstract][Full Text] [Related]
10. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Shinkai H
Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
[TBL] [Abstract][Full Text] [Related]
11. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
[TBL] [Abstract][Full Text] [Related]
12. Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.
Niesor EJ; Chaput E; Staempfli A; Blum D; Derks M; Kallend D
Atherosclerosis; 2011 Dec; 219(2):761-7. PubMed ID: 21982411
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.
Nicholls SJ; Ruotolo G; Brewer HB; Kane JP; Wang MD; Krueger KA; Adelman SJ; Nissen SE; Rader DJ
J Am Coll Cardiol; 2015 Nov; 66(20):2201-2210. PubMed ID: 26564598
[TBL] [Abstract][Full Text] [Related]
14. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.
Dong B; Singh AB; Fung C; Kan K; Liu J
Atherosclerosis; 2014 Aug; 235(2):449-62. PubMed ID: 24950000
[TBL] [Abstract][Full Text] [Related]
15. Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys.
Brodeur MR; Rhainds D; Charpentier D; Mihalache-Avram T; Mecteau M; Brand G; Chaput E; Perez A; Niesor EJ; Rhéaume E; Maugeais C; Tardif JC
J Lipid Res; 2017 Jul; 58(7):1282-1291. PubMed ID: 28515138
[TBL] [Abstract][Full Text] [Related]
16. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters.
Briand F; Thieblemont Q; Muzotte E; Sulpice T
Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):13-23. PubMed ID: 23139291
[TBL] [Abstract][Full Text] [Related]
17. Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters.
Briand F; Prunet-Marcassus B; Thieblemont Q; Costard C; Muzotte E; Sordello S; Sulpice T
Atherosclerosis; 2014 Apr; 233(2):359-362. PubMed ID: 24530763
[TBL] [Abstract][Full Text] [Related]
18. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
[TBL] [Abstract][Full Text] [Related]
19. Anacetrapib: a potential new therapy for dyslipidemia.
Robinson LB; Frishman WH
Cardiol Rev; 2014; 22(5):253-61. PubMed ID: 24618931
[TBL] [Abstract][Full Text] [Related]
20. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]